UK – NICE rejections continue, hitting Novo’s Saxenda next

Continuing a string of National Institute of Health and Care Excellence (NICE) rejections, Novo Nordisk’s weight management drug Saxenda (liraglutide) is next to take a hit from the organisation.

NICE has issued a draft guidance on the treatment, in which it is not recommended, within its marketing authorisation, for managing overweight and obesity in adults alongside a reduced-calorie diet and increased physical activity.

The decision was allegedly made as clinical trial evidence showed that Saxenda’s long-term effectiveness, particularly on reducing the risk of cardiovascular disease, is unknown despite the drug with lifestyle measures being more effective for weight loss…